Intraoperative Dexmedetomidine and Coronary Artery Bypass Graft Surgery
The Effect of Intraoperative Dexmedetomidine on Renal Function After Coronary Artery Bypass Graft Surgery
University of Novi Sad
100 participants
Apr 3, 2024
INTERVENTIONAL
Conditions
Summary
This is a prospective randomized clinical trial designed to determine the effect of intraoperative dexmedetomidine administration on renal function after coronary artery bypass graft surgery.
Eligibility
Inclusion Criteria4
- Elective coronary artery bypass graft surgery
- Age over 18 years
- ASA score 3 or 4
- Voluntary consent of the patient to participate in the research
Exclusion Criteria7
- Emergency coronary artery bypass graft surgery
- Chronic renal failure with eGFR <60 ml/min/1.73m2
- Left ventricular ejection fraction <30%
- nd or 3rd degree atrioventricular block
- Use of nephrotoxic agents such as aminoglycoside antibiotics or contrast agents within the last 48 hours
- Previous heart surgery or kidney surgery
- Allergy to dexmedetomidine
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine (200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml. Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06378827